Publications by authors named "T G Liston"

Article Synopsis
  • - AST-004 is a small molecule that targets adenosine receptors and shows promise for protecting the brain after strokes and injuries, aiming to assess its safety and how it's processed in the body during a phase I clinical trial on healthy individuals.
  • - The study involved giving varying doses of AST-004 to different groups of participants and then analyzing its levels in blood, cerebrospinal fluid (CSF), and urine; no serious side effects were observed, though headaches were reported by some.
  • - Findings indicated that AST-004 is safe at higher concentrations than previously effective in animal studies and that it reaches highest levels in CSF an hour after infusion, suggesting it may be suitable for further testing in treating strokes and brain injuries.
View Article and Find Full Text PDF
Article Synopsis
  • AST-004 is a small molecule being researched as a cerebroprotectant for acute stroke, requiring evaluation of its interactions with the only current stroke treatment, tPA (alteplase).
  • The study tested AST-004's stability and its effects on tPA's ability to break down clots using various in vitro methods, including assessing its performance in human blood.
  • Results showed that AST-004 does not interact negatively with alteplase or tenecteplase, suggesting it can be safely administered alongside these treatments for stroke patients.
View Article and Find Full Text PDF

A linear route has been used to prepare ()-methanocarba-nucleoside derivatives, which serve as purine receptor ligands having a pre-established, receptor-preferred conformation. To introduce this rigid ribose substitute, a Mitsunobu reaction of a [3.1.

View Article and Find Full Text PDF

The A adenosine receptor (AAR) is a target for pain, ischemia, and inflammatory disease therapy. Among the ligand tools available are selective agonists and antagonists, including radioligands, but most high-affinity non-nucleoside antagonists are limited in selectivity to primate species. We have explored the structure-activity relationship of a previously reported AAR antagonist DPTN (-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]nicotinamide) for radiolabeling, including 3-halo derivatives (3-iodo, MRS7907), and characterized as a high -affinity radioligand [H]MRS7799.

View Article and Find Full Text PDF

Acute ischemic stroke (AIS) is the second leading cause of death globally. No Food and Drug Administration (FDA) approved therapies exist that target cerebroprotection following stroke. Our group recently reported significant cerebroprotection with the adenosine A1/A3 receptor agonist, AST-004, in a transient stroke model in non-human primates (NHP) and in a preclinical mouse model of traumatic brain injury (TBI).

View Article and Find Full Text PDF